| 1 | Title: Vasoactive-Ventilation-Renal Score Reliably Predicts Hospital Length-of- |
|-----------|--|
| 2 | Stay after Surgery for Congenital Heart Disease |
| 3 1 | |
| 5 | Authors: |
| 6 | Bradley Scherer, MD |
| 7 | Department of Pediatrics, Indiana University School of Medicine |
| 8 | Riley Hospital for Children, Indianapolis, IN 46202 |
| 9 | |
| 10 | Elizabeth A. S. Moser, MS |
| 11 | Eairbanks School of Public Hoalth Indianapolis IN 46202 |
| 12 | |
| 14 | John W. Brown, MD |
| 15 | Department of Cardiac Surgery, Indiana University School of Medicine |
| 16 | Riley Hospital for Children, Indianapolis, IN 46202 |
| 17 | |
| 18 | Mark D. Rodefeld, MD Department of Cardiac Surgery, Indiana University School of Medicine |
| 20 | Riley Hospital for Children Indianapolis IN 46202 |
| 21 | |
| 22 | Mark W. Turrentine, MD |
| 23 | Department of Cardiac Surgery, Indiana University School of Medicine |
| 24 | Riley Hospital for Children, Indianapolis, IN 46202 |
| 25 | Christopher W. Mastropietra MD |
| 20 | Department of Pediatrics, Division of Critical Care, Indiana University School of Medicine |
| 28 | Rilev Hospital for Children. Indianapolis. IN 46202 |
| 29 | |
| 30 | |
| 31 | Corresponding author: |
| 32 22 | Christopher Mastropietro, MD |
| 33 34 | Department of Pediatrics Division of Critical Care Indiana University School of Medicine |
| 35 | Riley Hospital for Children, 705 Riley Hospital Drive |
| 36 | Indianapolis, IN 46202 |
| 37 | Phone #: 317-944-5165 |
| 38 | Fax #: 317-944-3442 |
| 39 | <u>cmastrop@iupui.edu</u> |
| 40 //1 | Funding: None |
| 42 | Tunung. Tone |
| 43 | Conflicts of Interest: The authors have no conflicts of interest to disclose. |
| 44 | |
| 45 | Word Count: 3173 |
| 46 47 | Indiana University IPP Protocol #1 1412065129 energy of 12/45/2014 12/44/2016 |
| 4/ | inuiana University ind Frotocol #. 1412903126, approved 12/15/2014 – 12/14/2016 |

This is the author's manuscript of the article published in final edited form as: Scherer, B., Moser, E. A., Brown, J. W., Rodefeld, M. D., Turrentine, M. W., & Mastropietro, C. W. (2016). Vasoactive-ventilation-renal score reliably predicts hospital length of stay after surgery for congenital heart disease. The Journal of thoracic and cardiovascular surgery, 152(5), 1423-1429. http://doi.org/10.1016/j.jtcvs.2016.07.070

Glossary of Abbreviations

- 53 AUC: area under the receiver operating characteristic curve
- **CI:** confidence interval
- **CPR:** cardiopulmonary resuscitation
- **CVICU:** cardiovascular intensive care unit
- **ΔCr:** change in serum creatinine from baseline
- **ECMO**: extracorporeal membrane oxygenation
- **FiO₂:** fraction of inspired oxygen
- **ICU:** intensive care unit
- 61 LOS: length of stay
- **IQR**: interquartile range
- 63 MAP: mean airway pressure
- **OR**: odds ratio
- **PEEP:** positive end expiratory pressure
- **PIP:** peak inspiratory pressure
- **ROC:** receiver operating characteristic
- **RR:** respiratory rate
- 69 STAT category: Society of Thoracic Surgeons-European Association for Cardio-
- 70 Thoracic Surgery Congenital Heart Surgery mortality category
- 71 VI: ventilation index
- 72 VIS: vasoactive-inotrope score
- 73 VVR: vasoactive-ventilation-renal score

78 Abstract

| 79 | Objectives: We aimed to further validate the vasoactive-ventilation-renal score (VVR) |
|-----|---|
| 80 | as a predictor of outcome in patients recovering from surgery for congenital heart |
| 81 | disease. We also sought to determine the optimal time point within the early recovery |
| 82 | period at which the VVR should be measured. |
| 83 | Methods: We prospectively reviewed consecutive patients recovering from cardiac |
| 84 | surgery within our ICU between 1/2015 – 6/2015. The VVR was calculated at 6, 12, 24, |
| 85 | and 48 hours postoperatively as follows: VVR = ventilation index + vasoactive-inotrope |
| 86 | score + Δ creatinine [change in serum creatinine from baseline*10]. Primary outcome of |
| 87 | interest was prolonged hospital length of stay (LOS), defined as LOS in the upper 25%. |
| 88 | Receiver operating characteristic curves were generated and areas under the curve |
| 89 | (AUC) with 95% confidence intervals (CI) were calculated for all time points. |
| 90 | Multivariable logistic regression modelling was also performed. |
| 91 | Results: We reviewed 164 patients, median age 9.25 months (interquartile range: 2.6 - |
| 92 | 58 months). Median LOS was 8 days (interquartile range: 5 - 17.5 days). The AUC |
| 93 | value for the VVR as a predictor of prolonged LOS (>17.5 days) was greatest at 12 |
| 94 | hours postoperatively, AUC=0.93 (95% CI: 0.89 - 0.97). On multivariable regression |
| 95 | analysis, after adjustment for potential confounders, the 12-hour VVR remained a strong |
| 96 | predictor of prolonged hospital LOS (OR: 1.15, 95% CI: 1.10, 1.20) |
| 97 | Conclusions: In a heterogeneous population of patients undergoing surgery for |
| 98 | congenital heart disease, the novel VVR calculated in the early postoperative recovery |
| 99 | period can be a strong predictor of prolonged hospital LOS. |
| 100 | Abstract Word Count: 249 |
| 101 | |
| 102 | |

104 Central Message

| 105 | The vasoactive-ventilation-renal score is a novel measure that robustly predicts outcome |
|-----|--|
| 106 | after surgery for congenital heart disease. |
| 107 | |
| 108 | |
| 109 | |
| 110 | |
| 111 | |
| 112 | |
| 113 | |
| 114 | |
| 115 | |
| 116 | |
| 117 | |
| 118 | |
| 119 | |
| 120 | |
| 121 | |
| 122 | |
| 124 | |
| 125 | |
| 126 | |
| 127 | |
| 128 | |
| 129 | |

130 Perspective Statement

| 131 | In this prospective study of patients undergoing surgery for congenital heart disease, the |
|-----|--|
| 132 | vasoactive-ventilation-renal score obtained 12 hours after ICU arrival was a strong |
| 133 | predictor of clinical outcome. This novel score could prove to be a powerful tool for |
| 134 | bedside assessment of illness severity and prognosis, triage of ICU resources, and |
| 135 | stratification of clinical research subjects. |
| 136 | |
| 137 | |
| 138 | |
| 139 | |
| 140 | |
| 141 | |
| 142 | |
| 143 | |
| 144 | |
| 145 | |
| 146 | |
| 147 | |
| 148 | |
| 149 | |
| 150 | |
| 151 | |
| 152 | |
| 153 | |
| 154 | |
| 155 | |

156 Central Image

182 Introduction

183 Scoring indices that can accurately reflect the severity of illness in critically-ill patients 184 can be extremely valuable in contemporary medicine, providing guidance in patient care 185 (e.g. triage, prognostication) and clinical research (e.g. stratification). The development 186 of a disease severity index for children recovering from cardiac surgery however has 187 been somewhat elusive, in large part due to the inherent heterogeneity of anatomy and 188 pathophysiology within this patient population. To this end, the novel vasoactive-189 ventilation-renal (VVR) score has recently demonstrated promise [1,2]. Specifically, the 190 VVR calculated at 48 hours postoperatively has been shown to be a robust predictor of 191 short-term clinical outcomes and consistently outperformed the vasoactive inotrope 192 score (VIS) and serum lactate, which have been used as more traditional measures of 193 postoperative disease severity [3-8].

194

195 Our previous studies of the VVR have had notable limitations. These studies have been 196 restricted to patients less than 18 years of age who have required cardiopulmonary 197 bypass. Adults undergoing surgery for congenital heart disease and children undergoing 198 cardiac surgery without cardiopulmonary bypass (e.g. systemic-to-pulmonary shunt, 199 pulmonary artery banding, etc.) have been excluded. Additionally, these prior reports 200 focused only on VVR measurements obtained at admission, peak and 48 hour 201 measurements. Peak and 48-hour VVR measurements in particular were chosen for 202 these initial studies because these measurements have been the focus of the majority of 203 research on the VIS.[3-5] The clinical utility of measurements obtained at specific 204 postoperative time points earlier in the postoperative course has not yet been 205 determined. To address these gaps in what is known regarding the VVR, we sought to 206 conduct a more inclusive prospective observational study examining the VVR score. We 207 postulated that the VVR would continue to be more predictive of outcomes as compared

| 208 | to the VIS and serum lactate in this broader population of patients recovering from |
|-----|--|
| 209 | surgery for congenital heart disease. We also sought to determine if the VVR obtained |
| 210 | at distinct time points earlier in the postoperative period, which would have more |
| 211 | practical clinical value, would be as predictive of postoperative outcomes as the VVR |
| 212 | calculated at 48 hours. |
| 213 | |
| 214 | Patients and Methods |
| 215 | Patient Population |
| 216 | This prospective observational validation study was approved by the Institutional Review |
| 217 | Board within the Office of Research Compliance at Indiana University. Due to the |
| 218 | observational nature of the study, consent was waived by the Institutional Review Board. |
| 219 | All patients admitted to the cardiovascular intensive care unit (CVICU) at Riley Hospital |
| 220 | for Children in Indianapolis, Indiana, from January 1, 2015 through June 30, 2015 were |
| 221 | prospectively reviewed. Patients who required extracorporeal membrane oxygenation |
| 222 | (ECMO) for the first 48 hours of CVICU admission were excluded, as their vasoactive |
| 223 | medication regimens and ventilator requirements would not be reflective of their |
| 224 | underlying disease severity but rather of the mechanical support provided by the |
| 225 | extracorporeal circuit. All other patients were followed throughout their clinical courses |
| 226 | and included in all analyses. |
| 227 | |

228 Data Collection

Pre- and perioperative data collected included: age, anthropometric measurements at
time of surgery, anatomic diagnosis and procedure performed, Society of Thoracic
Surgeons-European Association for Cardio-Thoracic Surgery Congenital Heart Surgery
mortality category (STAT mortality category),[9] cardiopulmonary bypass duration, aortic
cross-clamp duration, duration of hypothermic circulatory arrest if used, and preoperative

| 234 | serum creatinine values. All arterial blood gas and lactate measurements (which are |
|-----|---|
| 235 | performed simultaneously using point-of-care testing) obtained during the first 48 |
| 236 | postoperative hours were recorded daily by study personnel, along with the ventilator |
| 237 | support at the time of each measurement, which included respiratory rate (RR), fraction |
| 238 | of inspired oxygen (FiO ₂), peak inspiratory pressure (PIP), positive end expiratory |
| 239 | pressure (PEEP), and mean airway pressure (MAP). Patients at our institution are |
| 240 | typically managed postoperatively with synchronized intermittent mandatory ventilation / |
| 241 | pressure-regulated volume control, and typically extubated, at the discretion of the |
| 242 | primary care team, from mechanical ventilator support when breathing comfortably with |
| 243 | good gas exchange and without metabolic acidosis on the following ventilator settings: |
| 244 | respiratory rate \leq 10 breaths per minute, pressure support \leq 10 cmH ₂ O, positive end- |
| 245 | expiratory pressure \leq 5 cmH2O, and fraction of inspired oxygen concentration \leq 0.4. |
| 246 | Doses of inotropic and vasopressor medications (e.g. dopamine, dobutamine, |
| 247 | epinephrine, norepinephrine, milrinone, and vasopressin) at the time of each arterial |
| 248 | blood gas measurement were also recorded. Lastly, serum creatinine values obtained |
| 249 | on admission, postoperative day 1 and postoperative day 2 were recorded. |
| 250 | |
| 251 | Derivation of the Vasoactive Ventilation Renal Score |
| 252 | Throughout each patient's hospital course, we calculated the patients' VIS at the time of |
| 253 | each postoperative arterial blood gas measurement. The VIS was calculated in the |
| 254 | following manner [3]: |
| 255 | |

VIS = dopamine dose (mcg/kg/min) + dobutamine dose (mcg/kg/min) + 100 *
epinephrine dose (mcg/kg/min) + 10 * milrinone dose (mcg/kg/min) + 10,000 *
vasopressin dose (U/kg/min) + 100 * norepinephrine dose (mcg/kg/min).

259

| 260 | For patients on no vasoactive support at the time of blood gas measurement, VIS |
|-----|--|
| 261 | equaled zero. Secondly, the ventilation index (VI) was calculated for each postoperative |
| 262 | arterial blood gas measurement as follows [10]: |
| 263 | |
| 264 | VI = (Ventilator RR)*(PIP-PEEP)*PaCO ₂ / 1000 |
| 265 | |
| 266 | Use of the VI, which incorporates $PaCO_2$ rather than PaO_2 into its formula, permits the |
| 267 | inclusion of patients with mixing lesions and single ventricle anatomy in the study, as |
| 268 | $PaCO_2$ is less affected by intra-cardiac shunting. For patients not requiring mechanical |
| 269 | ventilation at the time of arterial blood gas measurement, VI equaled zero. Lastly, |
| 270 | baseline preoperative serum creatinine was subtracted from each postoperative serum |
| 271 | creatinine measurement (e.g. on admission, and postoperative days 1 and 2), which we |
| 272 | labeled ΔCr . For patients in which postoperative serum creatinine measurements were |
| 273 | less than or equal to baseline, we recorded $\Delta Cr = 0$. Creatinine was measured in |
| 274 | mg/dL. (For centers where creatinine is measured in mmol/L, we recommend converting |
| 275 | to mg/dL to calculate the score as follows: serum creatinine (mmol/dL) x 0.0113 = |
| 276 | serum creatinine (mg/dL)). |
| 277 | |
| 278 | Using each of these individual measurements, we then calculated the VVR at the time of |
| 279 | each arterial blood gas measurement as follows: |
| 280 | |
| 281 | $VVR = VIS + VI + (\Delta Cr * 10)$ |
| 282 | |
| 283 | VVR scores at 6, 12, 24, and 48 hours postoperatively were recorded. |
| 284 | |
| 285 | Statistical Analyses |
| | 10 |

286 Descriptive statistics are provided as medians with interguartile ranges (IQR) for 287 continuous variables and absolute counts with percentages for categorical variables. 288 The primary outcome of interest was hospital length of stay (LOS). We opted to focus 289 the study on hospital LOS because we deemed criteria for hospital discharge as 290 compared to ICU discharge to likely be less inconsistent across centers. Hospital LOS 291 is also inclusive of time spent in the ICU related to unplanned readmission after transfer to the cardiology ward. This outcome was dichotomized as upper (worst) 25th percentile 292 versus lower 75th percentile. Patients in the upper 25% were defined as having 293 294 prolonged LOS. Bivariate logistic regression analyses were performed to determine the 295 individual contributions of VVR, VIS and serum lactate as predictors of LOS. This 296 analysis was repeated for each of the four recorded time points. Receiver operative 297 characteristic (ROC) curves were generated and the abilities of the predictors to 298 correctly classify LOS were compared using area under the curve (AUC) values. AUC 299 values for VVR at the study time points were compared using the method of DeLong, 300 DeLong, and Clarke-Pearson as implemented by SAS.[11]

301

302 Bivariate comparisons were performed for demographic and surgical characteristics of 303 patients with and without prolonged LOS using Wilcoxon rank-sum tests, X-square test, 304 or Fisher's exact test as appropriate for individual variables. Variables that attained a 305 bivariate significance of \leq 0.30 and were of clinical relevance were considered for 306 inclusion in a multivariable logistic regression model. Linearity in the logit was examined 307 for continuous variables prior to model-building; those with evidence of non-linearity 308 were converted to categorical variables. To obtain the best model, stepwise selection 309 was used with a significance level of 0.3 for entry into the model, and 0.05 for staying. 310 All statistical analyses were performed using STATA version 13 and SAS version 9.4.

311

312 Results

313 Study Population

314 During the study period, 168 unique patients were admitted to the cardiovascular ICU 315 postoperatively. Four patients required ECMO support for the first 48 postoperative 316 hours and were excluded from analysis. All other patients (N=164) were included in the 317 analysis, median age 9.3 months (range: 1 day - 33 years). A summary of the 318 demographic and clinical characteristics of the patient cohort are shown in Table 1. 319 Median hospital LOS, our primary outcome variable, was 8 days (IQR: 5-17.5). 320 Prolonged LOS was therefore defined as greater than 17.5 days. Three patients died 321 before hospital discharge, all of which had prolonged hospital LOS prior to their deaths 322 (range 29 - 148 days). In addition, the hospital LOS for the four excluded patients who 323 required ECMO support for the first 48 hours ranged from 38 to 248 days, and none of 324 these patients died prior to hospital discharge.

325

326 Median serum lactate, VIS, and VVR measurements with IQR and maximum values are 327 presented in Table 2 for all study time points. We obtained ROC curves via bivariate 328 logistic regression analysis for 6, 12, 24, and 48-hour serum lactate, VIS, and VVR as 329 predictors of prolonged LOS. The AUC values for these models are also provided in 330 Table 2. Similar to our prior studies [1,2], VVR performed well and had a greater AUC 331 than the corresponding VIS and serum lactate at each time point (P < 0.05 for all 332 comparisons). We also performed ROC analysis for age, weight, duration of 333 cardiopulmonary bypass, and STAT category as predictors of prolonged LOS. The VVR 334 at each of the four study time points was more predictive of prolonged LOS than any of 335 these patient variables (P < 0.05 for all comparisons). The ROC curves for prolonged 336 LOS and serum lactate, VIS, and VVR at 12 hours postoperatively, as well as STAT 337 mortality category, are illustrated in Figure 2.

| 339 | The AUCs for the VVR at 6, 12, 24, and 48 hours are statistically compared to each |
|-----|--|
| 340 | other in Supplemental Table 2. There were no statistical differences between the ROC |
| 341 | curves for any of the VVR time points. In other words, the VVR at 6, 12, and 24 hours |
| 342 | were, at the very least, as predictive as the VVR at 48 hours. Of the four VVR |
| 343 | measurements, the 12-hour VVR had the highest AUC, 0.93 (95% Cls: 0.89-0.97). For |
| 344 | this reason, the remainder of the analysis is focused on this time point. |
| 345 | |
| 346 | Demographic and clinical variables for patients with and without prolonged hospital LOS |
| 347 | are compared in Table 3. All variables with <i>P</i> -value < 0.3 were considered for the |
| 348 | multivariable model. On multivariable regression analysis, the 12-hour VVR remained a |
| 349 | strong independent predictor of prolonged LOS. Specifically, with each increase of 1 in |
| 350 | a patient's 12-hour VVR score, the odds of a prolonged LOS increased by 15% (OR: |
| 351 | 1.15, 95% CI: 1.10, 1.20). Other variables that were independently associated with |
| 352 | prolonged LOS were the presence of non-cardiac anatomic abnormalities and the use of |
| 353 | inhaled nitric oxide. The remaining variables that were significant on bivariate analysis, |
| 354 | namely age, weight, STAT category 4 or 5, duration of cardiopulmonary bypass, and |
| 355 | admission lactate, were not significant on multivariable analysis and did not appreciably |
| 356 | affect the model. Delayed sternal closure and the need for CPR were not included in the |
| 357 | multivariable analysis because of the small number of patients within the study who had |
| 358 | these postoperative complications. The best multivariable model for prolonged LOS |
| 359 | including the 12-hour VVR, inhaled nitric oxide use, and non-cardiac anatomic |
| 360 | abnormalities is presented in Table 4. The AUC for the model was 0.94 (95% CI: 0.91, |
| 361 | 0.98). ROC curves for the model and its individual components are shown in Figure 2. |
| 362 | |

| 363 | To simplify the interpretation and use of the 12-hour VVR, we dichotomized the variable |
|-----|--|
| 364 | into high and low. A 12-hour VVR cutoff value of 25 was chosen to maximize total |
| 365 | accuracy and minimize weighted error ratios, and this cutoff correctly classified 90% of |
| 366 | patients. Patients with 12-hour VVR greater than or equal to 25 were therefore defined |
| 367 | as having a high VVR score. On multivariable logistic regression analysis, after |
| 368 | adjustment for the presence of inhaled nitric oxide and non-cardiac anatomic |
| 369 | abnormalities, high VVR at 12 hours remained strongly associated with prolonged LOS |
| 370 | (odds ratio: 31; 95% CI: 10 - 90). |
| 371 | |
| 372 | Comment |
| 373 | We have further validated the VVR as a multi-organ system severity of illness index for |
| 374 | patients recovering from surgery for congenital heart disease. We have now |
| 375 | demonstrated that the VVR strongly predicts hospital length of stay, more so than the |
| 376 | VIS and serum lactate, in a patient population that not only includes children requiring |
| 377 | cardiopulmonary bypass but also includes children undergoing procedures without |
| 378 | cardiopulmonary bypass and adults with congenital heart disease. The patients included |

in this study reflect the postoperative patient populations at many centers, where adults
undergoing surgery for congenital heart disease are commonly cared for within pediatric
cardiovascular ICU's [12,13]. The greater heterogeneity of the patient population in this
study has increased the strength and practicality of the VVR.

383

In our prior work, the VVR calculated at 48 hours was superior to admission and peak VVR measurements.[1,2] In fact, admission measurements performed poorly. This finding was not surprising, as vasoactive and ventilator support upon CVICU admission are likely less reflective of organ dysfunction and illness severity but rather more related to the dynamic processes that occur after cessation of cardiopulmonary bypass and

389 during transport to the CVICU. Likewise, the support upon admission may also be the 390 peak support, which will negatively affect the strength of peak VVR measurements. We 391 have now demonstrated that the VVR calculated at specific time points earlier in than 48 392 hours postoperatively can also reliably predict clinical outcome in children recovering 393 from cardiac surgery. Specifically, patients with a VVR score greater than or equal to 25 394 at the 12 hours postoperatively were 31 times more likely to have a prolonged length of 395 stay as compared to patients with lower VVR scores. This ability to provide important 396 prognostic data earlier in the postoperative course further increases the functionality of 397 the VVR.

398

399 The advantages of the VVR as compared to the VIS and serum lactate, as we have 400 discussed in our prior work [1,2], should be intuitive to physicians caring for these 401 children, as the VVR likely captures that subset of patients who have may have 402 preserved hemodynamic integrity yet have significant burden of disease from 403 postoperative lung or kidney injury. The additional components of the VVR, though on 404 the surface may seem cumbersome to some, can be obtained from routinely available 405 bedside data and the score can be quantitated with a simple calculator. Incorporation of 406 VVR calculation into the electronic medical record could further enhance its utility. If 407 available to physicians at the bedside, the 12-hour VVR has several potential clinical 408 applications. The 12-hour VVR could provide a reliable estimate of illness severity, give 409 parents and families realistic expectations of their child's postoperative course, or potentially assist with triage CVICU resources. Additionally, the 12-hour VVR could 410 411 help stratify potential research subjects or assist with propensity score matching. 412 Further validation in a multi-center data set should, however, be performed before 413 widespread application is recommended.

414

415 This study also found that the use of inhaled nitric oxide and the presence of non-cardiac 416 anatomic abnormalities had an effect on hospital LOS that was independent of the organ 417 dysfunction quantitated by the 12-hour VVR. Use of inhaled nitric oxide, in many cases, 418 represents an escalation of cardiopulmonary support beyond traditional vasoactive 419 medications and ventilatory support. It is therefore somewhat intuitive that its use is 420 associated with prolonged LOS, independent of the VVR. Likewise, the presence of 421 non-cardiac anatomic abnormalities such as airway anomalies or gastrointestinal defects 422 (e.g. intestinal malrotation, imperforate anus, Hirschsprung's disease) would not be 423 accounted for by the VVR yet could surely prolong LOS, especially if surgical 424 interventions were needed to address those abnormalities. Though the VVR at 12 hours 425 in and of itself was a solid predictor of prolonged LOS, addition of these important 426 variables further elevated the strength of our predictive model (Figure 2).

427

428 There are some limitations that must be noted. These data come from a single center, 429 which limits their generalizability. The initial work on the VVR was however completed at 430 a different center [1,2] and thus the VVR has now been validated as a predictor of 431 postoperative outcome at two different institutions with different cardiac surgeons and 432 varying practices. A multi-center validation study is the next step. Larger studies should 433 also determine if the VVR has the ability to predict additional outcomes (most important 434 of which is postoperative mortality), and whether other variables such as delayed sternal 435 closure or the need for CPR have an effect on outcome independent of the VVR. We 436 acknowledge that the VVR cannot reliably be calculated for patients requiring ECMO 437 support, though the need for ECMO in these patients, in and of itself, is considered by 438 most clinicians to be a reliable marker of disease severity. Indeed, all four patients who 439 were excluded due to ECMO support would be characterized as having prolonged LOS. 440 Also, no patients in our cohort required peritoneal dialysis or continuous renal

| 441 | replacement therapy within the first 48 hours postoperatively, but either modalities could |
|-----|--|
| 442 | also affect the reliability of the score. Finally, the VVR remains affected by limitations |
| 443 | previously noted in the VIS [3] - it does not assess the importance of the individual |
| 444 | components of the VIS, and vasoactive medication administration as well as the degree |
| 445 | of mechanical ventilator support were not under protocol and so may have been affected |
| 446 | by variation in physician practice. |
| 447 | |
| 448 | Conclusions |
| 449 | We have further validated the utility of the VVR score after surgery for congenital heart |
| 450 | disease. The VVR calculated at 12 hours postoperatively could be a valuable and |
| 451 | potentially powerful clinical tool to predict important postoperative outcomes in this |
| 452 | patient population. |
| 453 | |
| 454 | |
| 455 | |
| 456 | |
| 457 | |
| 458 | |
| 459 | |
| 460 | |
| 461 | |
| 462 | |
| 463 | |
| 464 | |
| 465 | |
| 466 | |

References

| 468 | 1. | Miletic KG, Spiering TJ, Delius RE, Walters HL 3rd, Mastropietro CW. |
|-----|----|--|
| 469 | | Use of a novel vasoactive-ventilation-renal score to predict outcomes after |
| 470 | | paediatric cardiac surgery. Interact Cardiovasc Thorac Surg. 2015;20:289- |
| 471 | | 95. |
| 472 | 2. | Miletic KG, Delius RE, Walters HL 3rd, Mastropietro CW. Prospective |
| 473 | | Validation of a Novel Vasoactive-Ventilation-Renal Score as a Predictor of |
| 474 | | Outcomes After Pediatric Cardiac Surgery. Ann Thorac Surg. 2016 Feb 9. |
| 475 | | Epub ahead of print. |
| 476 | 3. | Gaies MG, Jeffries HE, Niebler RA, Pasquali SK, Donohue JE, Yu S, et al. |
| 477 | | Vasoactive-inotropic score is associated with outcome after infant cardiac |
| 478 | | surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and |
| 479 | | Virtual PICU System Registries. Pediatr Crit Care Med. 2014;15:529-37. |
| 480 | 4. | Davidson J, Tong S, Hancock H, Hauck A, da Cruz E, Kaufman J. |
| 481 | | Prospective validation of the vasoactive-inotropic score and correlation to |
| 482 | | short-term outcomes in neonates and infants after cardiothoracic surgery. |
| 483 | | Intensive Care Med. 2012;38:1184-90. |
| 484 | 5. | Kalyanaraman M, DeCampli WM, Campbell AI, Bhalala U, Harmon TG, |
| 485 | | Sandiford P, et al. Serial blood lactate levels as a predictor of mortality in |
| 486 | | children after cardiopulmonary bypass surgery. Pediatr Crit Care Med. |
| 487 | | 2008;9:285-88. |
| 488 | 6. | Crow SS, Robinson JA, Burkhart HM, Dearani JA, Golden AW. Duration and |
| 489 | | magnitude of vasopressor support predicts poor outcome after infant cardiac |
| 490 | | operations. Ann Thorac Surg. 2014;98:655-61. |
| 491 | 7. | Friedland-Little JM, Hirsch-Romano JC, Sunkyung Yu, Donohue JE, Canada |
| 492 | | CE, Soraya P et al. Risk factors for requiring extracorporeal membrane |

| 493 | | oxygenation support after a Norwood operation. J Thorac Cardiovasc Surg. |
|-----|-----|--|
| 494 | | 2014;148:266-72. |
| 495 | 8. | Esch JJ, Salvin JM, Thiagarajan RR, del Nido PJ, Rajagopal SK. Acute |
| 496 | | kidney injury after Fontan completion: Risk factors and outcomes. J Thorac |
| 497 | | Cardiovasc Surg. 2015;150:190-7. |
| 498 | 9. | Jacobs JP, O'Brien SM, Pasquali SK, Jacobs ML, Lacour-Gayet FG, |
| 499 | | Tchervenkov CI, et al. Variation in outcomes for risk-stratified pediatric |
| 500 | | cardiac surgical operations: an analysis of the STS Congenital Heart Surgery |
| 501 | | Database. Ann Thorac Surg. 2012; 94:564-571. |
| 502 | 10. | Paret G, Ziv T, Barzilai A, Ben-Abraham R, Vardi A, Manisterski Y, Barzilay |
| 503 | | Z. Ventilation index and outcome in children with acute respiratory distress |
| 504 | | syndrome. Pediatr Pulmonol. 1998;26:125-8. |
| 505 | 11. | DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under |
| 506 | | two or more correlated receiver operating characteristic curves: a |
| 507 | | nonparametric approach. Biometrics. 1988 Sep;44(3):837-45. |
| 508 | 12. | Mahle WT, Kirshbom PM, Kanter KR, Kogon BM. Cardiac surgery in adults |
| 509 | | performed at children's hospitals: trends and outcomes. J Thorac Cardiovasc |
| 510 | | Surg. 2008;136:307-11. |
| 511 | 13. | May LJ, Longhurst CA, Pageler NM, Wood MS, Sharek PJ, Zebrack CM. |
| 512 | | Optimizing care of adults with congenital heart disease in a pediatric |
| 513 | | cardiovascular ICU using electronic clinical decision support. Pediatr Crit |
| 514 | | Care Med. 2014;15:428-34. |
| 515 | | Y |
| 516 | | |
| 517 | | |
| 518 | | |

Figure Legends

- **Figure 1:** Receiver Operating Characteristic (ROC) curves for prolonged hospital length
- 521 of stay and serum lactate (green), vasoactive-inotrope score (VIS) (red), vasoactive-
- 522 ventilation-renal (VVR) score at 12 hours postoperatively (blue), along with STAT
- 523 category (orange). The AUC was greatest for the VVR at 12 hours postoperatively,
- *P*<0.001 for all comparisons.
- **Figure 2:** Receiver Operating Characteristic (ROC) curves for prolonged hospital length
- 526 of stay and the multivariable model (solid blue line) and its individual components
- 527 (dashed lines): vasoactive-ventilation-renal (VVR) score at 12 hours postoperatively
- 528 (red), inhaled nitric oxide (purple), and non-cardiac anatomic abnormalities (green).
- 529 Area under the curve for the multivariable model was 0.94 (95% CI: 0.91 0.98).

540 Video Legend

- 541 Video: Dr. Mastropietro explains the inception of the vasoactive-ventilation-renal score
- 542 as an index of disease severity for infants and children who undergo cardiovascular
- 543 surgery, and comments on the significance of the findings presented in their latest study.
- 544

| 545 | |
|------------|--|
| 546 | |
| 547 | |
| 548 | |
| 549 | |
| 550 | |
| 551 | |
| 552 | |
| 553 | |
| 554 555 | |
| 556 | |
| 557 | |
| 558 | |
| 559 | |
| 560 | |
| 561 | |
| 562 | |
| 563 | |
| 564 565 | |
| 566 | |
| 567 | |
| 568 | |
| | |
| | |
| | |

Tables

Table 1: Patient Demographic Characteristics

| Characteristic | All Patients (n=164) |
|--|----------------------|
| Age (months) | 9.3 (2.6 – 57.8) |
| Male (n) | 102 (62%) |
| Weight (kg) | 7.8 (4.6 – 17.8) |
| Race (n) | |
| Caucasian | 131 (80%) |
| African American | 23 (14%) |
| Asian | 7 (4%) |
| Other | 3 (2%) |
| Genetic / chromosomal abnormalities (n) | 35 (21%) |
| Trisomy 21 | 17 (10%) |
| Other | 18 (11%) |
| Non-cardiac anatomic abnormalities (n) | 30 (18%) |
| STAT category (n) | |
| 1 | 52 (32%) |
| 2 | 41 (25%) |
| 3 | 31 (19%) |
| 4 | 31 (19%) |
| 5 | 7 (4%) |
| Other | 2 (1%) |
| Preoperative creatinine (mg/dL) | 0.35 (0.29 - 0.50) |
| Cardiopulmonary bypass duration (min) | 88 (59 -136) |
| Aortic cross clamp duration (min) | 42 (15 – 66) |
| Delayed sternal closure (n) | 16 (10%) |
| Postoperative inhaled nitric oxide use (n) | 27 (16%) |
| Admission lactate (mg/dL) | 2.0 (1.3 - 2.9) |
| Postoperative CPR (n) | 6 (4%) |

CPR: cardiopulmonary resuscitation; STAT: Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Congenital Heart Surgery mortality category

Data represented as absolute counts (%) or median (interquartile range)

| Postoperative Variables | | Median (IQR) Maximum | | AUC (95% CI) | |
|-------------------------|-------------------------|----------------------|----------|--------------------|--|
| 6-hour | 6-hours: | | | | |
| | Lactate (mg/dL) | 1.3 (0.8 - 2.6) | 9.2 | 0.75 (0.67 - 0.84) | |
| | VIS | 0 (0 - 5) | 15.5 | 0.81 (0.74 - 0.88) | |
| | VVR | 5.2 (0.6 - 24.3) | 96 | 0.93 (0.89 - 0.97) | |
| 12-hours: | | | | <u></u> | |
| | Lactate (mg/dL) | 1.1 (0.7 - 1.9) | 9.7 | 0.78 (0.71 - 0.86) | |
| | VIS | 0 (0 - 5) | 16 | 0.81 (0.73 - 0.88) | |
| | VVR ^a | 3.5 (0.2 - 24.6) | 75 | 0.93 (0.89 - 0.97) | |
| 24-hours: | | | | | |
| Lactate (mg/dL) | | 0.9 (0.7 - 1.4) | 5.4 | 0.61 (0.52 - 0.71) | |
| | VIS | 0 (0 - 5) | 17 | 0.84 (0.77 - 0.91) | |
| | VVR | 1.7 (0 - 20.9) | 64 | 0.91 (0.84 - 0.97) | |
| 48-hours: | | | | | |
| | Lactate (mg/dL) | 0.85 (0.6 - 1.3) | 5.4 | 0.55 (0.45 - 0.65) | |
| | VIS | 0 (0 - 4.5) | 17.5 | 0.83 (0.76 - 0.91) | |
| | VVR | 0.5 (0-11.1) | 64 | 0.89 (0.81 - 0.96) | |
| Age (months) | | 9.3 (2.6 - 57.8) | 33 years | 0.78 (0.70 - 0.87) | |
| Weight (kg) | | 7.8 (4.6 -17.8) | 100 | 0.80 (0.72 - 0.88) | |
| STAT | category | 2 (1 - 3) | 5 | 0.79 (0.72 - 0.87) | |
| CPB duration (min) | | 87.5 (59 -136) | 345 | 0.66 (0.55 - 0.77) | |

Table 2: Relationship between postoperative measurements and prolonged LOS

^a AUC for VVR at 12 hours was 0.933, slightly greater than AUC for VVR at 6 hours of 0.929 AUC: Area under the receiver operating characteristic curve; CPB: cardiopulmonary bypass; CI: confidence interval; IQR: interquartile range; LOS: hospital length of stay; STAT: Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Congenital Heart Surgery mortality category; VIS: vasoactive inotrope score; VVR: vasoactive-ventilation-renal score

| Characteristic | Prolonged LOS | No Prolonged | P-value |
|-----------------------------------|--------------------|--------------------|---------|
| | (n=41) | LOS (n=123) | _ |
| Age (months) | 1.5 (0.3 - 6.5) | 11.5 (6.3 - 80) | <0.001 |
| Male (n) | 28 (68%) | 74 (60%) | 0.35 |
| Weight (kg) | 4.2 (3.4 - 5.5) | 8.5 (6.1 - 22.3) | < 0.001 |
| Genetic abnormalities (n) | 7 (17%) | 28 (23%) | 0.44 |
| NCAA (n) | 13 (32%) | 17 (14%) | 0.01 |
| STAT category 4 or 5 (n) | 21 (51%) | 17 (14%) | <0.001 |
| Preoperative creatinine (mg/dL) | 0.35 (0.29 - 0.48) | 0.35 (0.29 - 0.51) | 0.42 |
| CPB Duration (min) | 129 (78 - 173) | 82 (56 - 122) | 0.002 |
| Aortic cross clamp duration (min) | 53 (22 - 70) | 36 (14 - 60) | 0.13 |
| Delayed sternal closure (n) | 15 (37%) | 1 (1%) | <0.001 |
| Postoperative iNO use (n) | 19 (46%) | 8 (7%) | <0.001 |
| Admission lactate (mg/dL) | 2.3 (1.7 - 5) | 1.9 (1.3 - 2.7) | 0.004 |
| VVR at 12 hours | 31 (27 - 40) | 1 (0 - 11) | <0.001 |

Table 3. Bivariate Analysis Comparing Patients With and Without Prolonged LOS

CPB: Cardiopulmonary bypass; *iNO*: inhaled nitric oxide; *NCAA*: non-cardiac anatomic abnormalities; *STAT*: Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Congenital Heart Surgery mortality category; *VVR*: vasoactive-ventilation-renal score

Data represented as absolute counts (%) or median (interquartile range)

Ċ

| Parameter | Estimate | SE | P-value | Odds Ratio (95% CI) |
|------------------------------------|----------|------|---------|---------------------|
| Intercept | -4.20 | 0.64 | <0.0001 | - |
| 12-hour VVR | 0.14 | 0.02 | <0.0001 | 1.15 (1.10, 1.20) |
| Inhaled nitric oxide | 1.50 | 0.71 | 0.033 | 4.50 (1.13, 17.99) |
| Non-cardiac anatomic abnormalities | 1.54 | 0.73 | 0.034 | 4.67 (1.13, 19.34) |

Table 4. Multivariable Regression Analysis for Predictors of Prolonged LOS

CI: Confidence interval; LOS: length of stay; SE: standard error; VVR: vasoactive-ventilation-renal score

| Supplemental Table 1. | Cardiovascular Surgical Procedures Organized by STAT Mortality |
|-----------------------|--|
| Categories | |

| Primary surgical procedure | All Patients (N=164) |
|---|-------------------------|
| STAT Category 1 | 52 (32%) |
| Repair, atrial septal defect | 9 |
| Repair, ventricular septal defect | 13 |
| Repair, Tetralogy of Fallot | 9 |
| Pulmonary valve replacement | 7 |
| Lateral tunnel Fontan operation | 4 |
| Repair, partial atrioventricular canal defect | 3 |
| Other | 7 |
| STAT Category 2 | 41 (25%) |
| Repair, coarctation of the aorta | 8 |
| Aortic valvuloplasty | 6 |
| Repair, Tetralogy of Fallot | 4 |
| Extracardiac Fontan operation | 3 |
| Bidirectional Glenn operation | 3 |
| Other | 17 |
| STAT Category 3 | 31 (18%) |
| Arterial Switch procedure (d-TGA w/IVS) | 5 |
| Hemi-Fontan operation | 6 |
| AV-Canal | 5 |
| Repair, pulmonary atresia w/VSD | 5 |
| Right ventricle-to-pulmonary artery conduit | 4 |
| Other | 6 |
| STAT Category 4 | 31 (19%) |
| Systemic-to-pulmonary artery shunt | 7 |
| Orthotopic heart transplant | 5 |
| Repair, total anomalous pulmonary venous return | 5 |
| Arterial switch procedure (d-TGA w/VSD) | 2 |
| Pulmonary artery banding | 3 |
| Other | 9 |
| STAT Category 5 | 7 (4%) |
| Norwood operation | 6 |
| Damus-Kaye Stanzel operation | 1 |

d-TGA: d-transposition of the great arteries; IVS: intact ventricular septum; VSD: ventricular septal defect

Supplemental Table 2. Statistical Comparison for Area under the Curve Values for the Vasoactive-Ventilation-Renal (VVR) score and Prolonged Length of Stay at 6, 12, 24, and 48 hours.

| Contrast | Estimate | SE | 95% W | ald CL | Chi-Square | P-value |
|-----------------------|----------|--------|---------|--------|------------|---------|
| VVR 6 hr - VVR 12 hr | -0.00366 | 0.0105 | -0.0242 | 0.0169 | 0.1213 | 0.73 |
| VVR 6 hr - VVR 24 hr | 0.0210 | 0.0252 | -0.0283 | 0.0704 | 0.6978 | 0.40 |
| VVR 6 hr - VVR 48 hr | 0.0403 | 0.0280 | -0.0145 | 0.0952 | 2.0787 | 0.15 |
| VVR 12 hr - VVR 24 hr | 0.0247 | 0.0232 | -0.0208 | 0.0702 | 1.1335 | 0.29 |
| VVR 12 hr - VVR 48 hr | 0.0440 | 0.0282 | -0.0112 | 0.0992 | 2.4421 | 0.12 |
| VVR 24 hr - VVR 48 hr | 0.0193 | 0.0197 | -0.0192 | 0.0578 | 0.9656 | 0.33 |

ACCEPTED MANUSCRIPT





Vasoactive-Ventilation-Renal Score Reliably Predicts Hospital Lengthof-Stay after Surgery for Congenital Heart Disease